HeartBeam (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

At a glance

Company: HeartBeam, Inc.
Ticker: NASDAQ: BEAT

Key figures

Patients evaluated: 184
AUC using one ECG reading, risk factors and symptoms: 86.5%
AUC with a symptom-free baseline ECG: 92.9%

Products and programs

HeartBeam ECG device
HeartBeam System
12-lead ECG synthesis software

HeartBeam (NASDAQ: BEAT) a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain.

HeartBeam said the proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.

To view the full press release, visit https://ibn.fm/ainxV

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.

(1)Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

HeartBeam, Inc. says a peer-reviewed article in JACC: Advances reported findings from a proof-of-concept study of an algorithm using ECG readings from its portable device. The study included 184 patients with chest pain. According to the company, the algorithm’s area-under-the-curve result was 86.5% when it used one HeartBeam ECG reading alongside patient risk factors and symptoms. The result was 92.9% when a personal ECG recorded while the patient was symptom-free was also available for comparison. HeartBeam says the findings support further work on heart attack detection as a potential indication for its system and contribute to its wider clinical program. The release notes that the company’s ECG technology and synthesis software have received FDA clearances for arrhythmia assessment.

Key takeaways

A peer-reviewed article reported results from a HeartBeam algorithm study involving 184 patients with chest pain.
The company reported an AUC of 86.5% using one ECG reading with patient risk factors and symptoms.
The reported AUC was 92.9% when a symptom-free personal ECG baseline was available.
HeartBeam says the findings support continued clinical work on heart attack detection as a potential indication.

SEC filings

Earlier from HeartBeam, Inc.

Back to News Center